Structural propensities of kinase family proteins from a Potts model of residue co-variation

Protein Science

Volumn , Issue , 2016, Pages 1378-1384

  Haldane, Allan ^a   Flynn, William F ^a,b   He, Peng ^a   Vijayan, R S K ^a   Levy, Ronald M ^a  

^a Temple University   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

co evolution; conformational preference; inhibitor specificity; kinase; Potts model

Indexed keywords

ENZYME INHIBITOR; PHOSPHOTRANSFERASE;

ALGORITHM; AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BINDING ASSAY; C HELIX REGION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENERGY; INVERSE ISING METHOD; MATHEMATICAL MODEL; POINT MUTATION; POTTS HAMILTONIAN MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MOTIF;

EID: 84978997426     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2954     Document Type: Article

References (47)

1. Lovera S, Sutto L, Boubeva R, Scapozza L, Dlker N, Gervasio FL (2012) The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J Am Chem Soc 134:2496–2499.
2. Lin YL, Meng Y, Jiang W, Roux B (2013) Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc Natl Acad Sci 110:1664–1669.
3. Aleksandrov A, Simonson T (2010) Molecular dynamics simulations show that conformational selection governs the binding preferences of Imatinib for several tyrosine kinases. J Biol Chem 285:13807–13815.
4. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942.
5. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J (2007) c-Src binds to the cancer drug Imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15:299–311.
6. Vijayan RSK, He P, Modi V, Duong-Ly KC, Ma H, Peterson JR, Dunbrack RL, Levy RM (2015) Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem 58:466–479.
7. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358–364.
8. Mbitz H (2015) The ABC of protein kinase conformations. Biochim et Biophys Acta 1854:1555–1566.
9. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ (2009) Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res 69:2384–2392.
10. Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, Halpin J, Buosi V, Otten R, Waterman D, Theobald DL, Kern D (2015) Using ancient protein kinases to unravel a modern cancer drugs mechanism. Science 347:882–886.
11. Agafonov RV, Wilson C, Otten R, Buosi V, Kern D (2014) Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nat Struct Mol Biol 21:848–853.
12. de Juan D, Pazos F, Valencia A (2013) Emerging methods in protein co-evolution. Nat Rev Genet 14:249–261.
13. Marks DS, Hopf TA, Sander C (2012) Protein structure prediction from sequence variation. Nat Biotech 30:1072–1080.
14. Weigt M, White RA, Szurmant H, Hoch JA, Hwa T (2009) Identification of direct residue contacts in proteinprotein interaction by message passing. pnas 106:67–72.
15. Lvkvist C, Lan Y, Weigt M, Aurell E, Ekeberg M (2013) Improved contact prediction in proteins: using pseudolikelihoods to infer potts models. Phys Rev E 87:012707.
16. Morcos F, Jana B, Hwa T, Onuchic JN (2013) Coevolutionary signals across protein lineages help capture multiple protein conformations. Proc Natl Acad Sci 110:20533–20538.
17. Sukowska JI, Morcos F, Weigt M, Hwa T, Onuchic JN (2012) Genomics-aided structure prediction. Proc Natl Acad Sci 109:10340–10345.
18. Morcos F, Pagnani A, Lunt B, Bertolino A, Marks DS, Sander C, Zecchina R, Onuchic JN, Hwa T, Weigt M (2011) Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proc Natl Acad Sci 108:E1293–E1301.
19. dos Santos RN, Morcos F, Jana B, Andricopulo AD, Onuchic JN (2015) Dimeric interactions and complex formation using direct coevolutionary couplings. Sci Rep 5:13652.
20. Marks DS, Colwell LJ, Sheridan R, Hopf TA, Pagnani A, Zecchina R, Sander C (2011) Protein 3D structure computed from evolutionary sequence variation. PLoS One 6:e28766EP.
21. Morcos F, Schafer NP, Cheng RR, Onuchic JN, Wolynes PG (2014) Coevolutionary information, protein folding landscapes, and the thermodynamics of natural selection. Proc Natl Acad Sci 111:12408–12413.
22. Cheng RR, Raghunathan M, Noel JK, Onuchic JN (2015) Constructing sequence-dependent protein models using coevolutionary information. Prot Sci 25:111122.
23. Lapedes A, Giraud B, Jarzynski C (2002) Using sequence alignments to predict protein structure and stability with high accuracy. arXiv:1207.2484
24. Mzard M, Mora T (2009) Constraint satisfaction problems and neural networks: a statistical physics perspective. J Physiol-Paris 103:107–113.
25. Weigt M, White RA, Szurmant H, Hoch JA, Hwa T (2009) Identification of direct residue contacts in proteinprotein interaction by message passing. Proc Natl Acad Sci 106:67–72.
26. Monasson R, Cocco S (2011) Adaptive cluster expansion for inferring boltzmann machines with noisy data. Phys Rev Lett 106:090601.
27. Jones DT, Buchan DWA, Cozzetto D, Pontil M (2012) PSICOV: precise structural contact prediction using sparse inverse covariance estimation on large multiple sequence alignments. Bioinformatics 28:184–190.
28. Balakrishnan S, Kamisetty H, Carbonell JG, Lee SI, Langmead CJ (2011) Learning generative models for protein fold families. Prot Struct, Funct, Bioinform 79:1061–1078.
29. Burger L, van Nimwegen E (2010) Disentangling direct from indirect co-evolution of residues in protein alignments. PLoS Comput Biol 6:e1000633.
30. Baldassi C, Zamparo M, Feinauer C, Procaccini A, Zecchina R, Weigt M, Pagnani A (2014) Fast and accurate multivariate gaussian modeling of protein families: predicting residue contacts and protein-interaction partners. PLoS ONE 9:e92721EP.
31. Sutto L, Marsili S, Valencia A, Gervasio FL (2015) From residue coevolution to protein conformational ensembles and functional dynamics. Proc Natl Acad Sci 112:13567–13572.
32. Mora T, Bialek W (2011) Are biological systems poised at criticality? J Stat Phys 144:268–302.
33. Ferguson A, Mann J, Omarjee S, Ndungu T, Walker B, Chakraborty A (2013) Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38:606–617.
34. Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE (2006) The structure of Dasatinib (BMS-0000) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants. Cancer Research 66:5790–5797.
35. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI–571). Cancer Research 62:4236–4243.
36. Guimares CRW, Rai BK, Munchhof MJ, Liu S, Wang J, Bhattacharya SK, Buckbinder L (2011) Understanding the impact of the P-loop conformation on kinase selectivity. J Chem Inf Model 51:1199–1204.
37. Taylor SS, Kornev AP (2011) Protein kinases: evolution of dynamic regulatory proteins. Trend Biochem Sci 36:65–77.
38. Huang H, Zhao R, Dickson BM, Skeel RD, Post CB (2012) αC (alpha-C) helix as a switch in the conformational transition of Src/CDK-like kinase domains. J Phys Chem B 116:4465–4475.
39. Shan Y, Arkhipov A, Kim ET, Pan AC, Shaw DE (2013) Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci 110:7270–7275.
40. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 29:1046–1051.
41. Lovera S, Morando M, Pucheta-Martinez E, Martinez-Torrecuadrada JL, Saladino G, Gervasio FL (2015) Towards a molecular understanding of the link between Imatinib resistance and kinase conformational dynamics. PLoS Comput Biol 11:e1004578EP.
42. Bavetsias V, Linardopoulos S (2015) Aurora kinase inhibitors: current status and outlook. Front Oncol 5:
43. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA (2012) Aurora a kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 70:661–687.
44. Heron NM, Anderson M, Blowers DP, Breed J, Eden JM, Green S, Hill GB, Johnson T, Jung FH, McMiken HH, Mortlock AA, Pannifer AD, Pauptit RA, Pink J, Roberts NJ, Rowsell S (2006) SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett 16:1320–1323.
45. Remmert M, Biegert A, Hauser A, Soding J (2012) HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment. Nat Meth 9:173–175.
46. van Linden OPJ, Kooistra AJ, Leurs R, de Esch IJP, de Graaf C (2014) KLIFS: a knowledge-based structural database to navigate kinaseligand interaction space. J Med Chem 57:249–277.
47. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW (2013) Genbank. Nucleic Acid Res 41:D36–D42.